Brokers Offer Predictions for Oncobiologics Q3 Earnings

Oncobiologics, Inc. (NASDAQ:OTLK) – Analysts at Brookline Capital Markets raised their Q3 2026 EPS estimates for Oncobiologics in a research report issued to clients and investors on Monday, March 30th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will post earnings of ($0.13) per share for the quarter, up from their previous forecast of ($0.17). The consensus estimate for Oncobiologics’ current full-year earnings is ($2.27) per share. Brookline Capital Markets also issued estimates for Oncobiologics’ Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.55) EPS and FY2027 earnings at ($0.14) EPS.

Oncobiologics (NASDAQ:OTLK) last issued its quarterly earnings data on Tuesday, February 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.05). The business had revenue of ($1.21) million for the quarter, compared to analysts’ expectations of $3.14 million.

OTLK has been the topic of a number of other reports. Wall Street Zen lowered Oncobiologics from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncobiologics in a report on Friday, March 27th. Chardan Capital reaffirmed a “neutral” rating on shares of Oncobiologics in a report on Wednesday, February 18th. Ascendiant Capital Markets decreased their price objective on Oncobiologics from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, March 11th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Oncobiologics in a report on Wednesday, February 18th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $4.50.

Oncobiologics Stock Up 17.4%

Shares of OTLK stock opened at $0.25 on Tuesday. The firm has a 50 day moving average price of $0.37 and a two-hundred day moving average price of $1.00. The company has a market capitalization of $21.16 million, a PE ratio of -0.10 and a beta of 0.18. Oncobiologics has a 12-month low of $0.16 and a 12-month high of $3.39.

Institutional Investors Weigh In On Oncobiologics

A number of large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its position in Oncobiologics by 74.1% during the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after buying an additional 44,063 shares in the last quarter. AQR Capital Management LLC grew its position in Oncobiologics by 42.7% during the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock worth $103,000 after buying an additional 25,351 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in Oncobiologics by 865.2% in the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after purchasing an additional 21,941 shares in the last quarter. Institutional investors and hedge funds own 11.20% of the company’s stock.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.